Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 105.01%20.18K | 103.32%26.68K | 77.08%-44.2K | -64.17%-2.43M | -645.57%-1.03M | 59.86%-403.11K | -137.08%-804.59K | -6,475.66%-192.8K | -313.45%-1.48M | -21.28%-137.72K |
| Net income from continuing operations | 355.31%14.25M | 2,883.20%11.03M | 82.83%-269.49K | 136.86%3.16M | 179.31%2M | 240.73%3.13M | 76.17%-396.48K | 27.82%-1.57M | -2,367.21%-8.58M | 18.44%-2.52M |
| Operating gains losses | -334.30%-14.62M | -2,827.19%-11.39M | -101.25%-14.13K | -185.14%-5.03M | -289.07%-2.4M | -291.29%-3.37M | -136.12%-389.04K | -36.96%1.13M | 584.65%5.9M | -52.63%1.27M |
| Depreciation and amortization | -14.94%615 | -2.36%663 | 5.29%716 | -57.30%2.75K | -74.63%669 | -34.39%723 | -41.77%679 | -55.76%680 | 16.66%6.44K | 100.53%2.64K |
| Asset impairment expenditure | ---- | ---- | ---- | ---197.27K | ---- | ---- | ---- | ---- | --0 | ---- |
| Deferred tax | ---- | ---- | ---- | 284.69%127.22K | ---- | ---- | ---- | ---- | ---68.88K | ---- |
| Other non cashItems | 209.42%25.91K | 8,828.57%25.63K | ---1 | ---- | ---- | ---23.68K | --287 | ---- | 221.02%144.62K | ---- |
| Change In working capital | 362.51%372K | -3,005.63%-613.33K | -2.25%238.71K | -139.36%-498.27K | -148.18%-569.32K | 73.87%-141.71K | -108.03%-19.75K | -35.81%244.21K | 98.50%1.27M | 182.98%1.18M |
| -Change in receivables | 24.71%14.3K | -16.06%-13.45K | -92.65%673 | 283.38%12.41K | -96.97%3.38K | 110.62%11.47K | -3.44%-11.59K | 989.40%9.15K | -274.81%-6.77K | 610.11%111.56K |
| -Change in prepaid assets | 6,853.78%17.45K | -8,722.05%-57.08K | 86.74%-772 | -118.55%-1.12K | 678.23%3.79K | -91.58%251 | -77.54%662 | -1,457.22%-5.82K | 173.78%6.04K | -87.71%487 |
| -Change in payables and accrued expense | 321.77%340.25K | -6,174.41%-542.8K | 4.41%238.8K | -144.38%-497.88K | -161.06%-564.81K | 64.93%-153.42K | -103.40%-8.65K | -39.81%228.72K | 78.89%1.12M | 124.10%925.02K |
| -Change in other working capital | ---- | ---- | ---- | -108.08%-11.69K | ---- | ---- | ---169 | --12.16K | 872.67%144.62K | ---- |
| Dividends received (cash flow from operating activities) | --0 | --966.67K | ---- | ---- | ---- | --0 | --0 | ---- | --0 | ---- |
| Tax refund paid | --0 | ---- | ---- | ---4 | --0 | ---4 | ---- | ---- | --0 | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 105.01%20.18K | 103.32%26.68K | 77.07%-44.2K | -64.17%-2.43M | -645.57%-1.03M | 59.86%-403.11K | -137.00%-804.31K | -6,475.66%-192.8K | -313.45%-1.48M | -21.28%-137.72K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 0 | 0 | -3.24K | -1.3K | 0 | -1.94K | 0 | 0 | ||
| Capital expenditure reported | --0 | --0 | ---- | ---- | ---- | --0 | ---1.94K | ---- | --0 | --0 |
| Net PPE purchase and sale | ---- | ---- | ---- | ---3.24K | ---- | ---- | ---- | ---- | --0 | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | --0 | --0 | ---- | ---3.24K | ---1.3K | --0 | ---1.94K | ---- | --0 | --0 |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 0 | 0 | 45.82%2.35M | 1.09M | -79.27%277.78K | 264.79%984.93K | 1.61M | 0 | ||
| Net issuance payments of debt | --0 | --0 | ---- | --2.35M | --1.09M | --277.78K | --984.93K | ---- | ---- | ---- |
| Net common stock issuance | ---- | ---- | ---- | --0 | --0 | --0 | ---- | ---- | --1.34M | --0 |
| Proceeds from stock option exercised by employees | --0 | --0 | ---- | --0 | --0 | --0 | ---- | ---- | --270K | --0 |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | --0 | --0 | ---- | 45.82%2.35M | --1.09M | -79.27%277.78K | 264.79%984.93K | ---- | --1.61M | --0 |
| Net cash flow | ||||||||||
| Beginning cash position | -34.70%166.36K | 90.63%140.22K | -30.75%184.31K | 97.32%266.16K | -68.67%126.54K | 272.60%254.77K | -46.88%73.55K | 97.32%266.16K | -72.90%134.89K | 63.14%403.88K |
| Current changes in cash | 116.10%20.18K | -85.07%26.68K | 77.07%-44.2K | -162.65%-82.47K | 141.37%56.97K | -137.33%-125.33K | 357.58%178.69K | -6,475.66%-192.8K | 136.37%131.63K | -21.28%-137.72K |
| Effect of exchange rate changes | 199.59%2.89K | -121.15%-534 | -45.96%107 | 271.63%623 | 8,150.00%805 | -1,411.98%-2.9K | 446.36%2.53K | -65.14%198 | 60.11%-363 | -101.16%-10 |
| End cash Position | 49.71%189.44K | -34.70%166.36K | 90.63%140.22K | -30.75%184.31K | -30.75%184.31K | -68.67%126.54K | 272.60%254.77K | -46.88%73.55K | 97.32%266.16K | 97.32%266.16K |
| Free cash from | 105.01%20.18K | 103.31%26.68K | 77.07%-44.2K | -64.39%-2.43M | -646.51%-1.03M | 59.86%-403.11K | -137.57%-806.24K | -6,475.66%-192.8K | -308.47%-1.48M | -21.28%-137.72K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.